The test could help identify one key Alzheimer's biomarker, tau protein, before it shows up in brain. Here's what experts say ...

Doug Whitney was supposed to develop Alzheimer's by 50. Now scientists are trying to understand why his brain remains healthy ...

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

Scientists believe they have found a major link between Alzheimer's disease and a dieting hack, which is followed by millions ...

Intermittent fasting may be the key to slowing or even reversing the signs of Alzheimer's disease, a new study suggests.

Leqembi (lecanemab) and Kisunla (donanemab) are proven to slow cognitive and functional decline by 27 and 35%, respectively.

A complementary drug to combat Alzheimer's disease could target a specific part of the nerve cell protein tau. This is the finding of new research which also offers a better way to measure the effect ...

A new biomarker test identifies very early stages of tau tangle formation, up to a decade before any tau clumps can show up ...

A complementary drug to combat Alzheimer’s disease could target a specific part of the nerve cell protein tau.

PITTSBURGH (KDKA) — A breakthrough in the fight against Alzheimer's was made by researchers at the University of Pittsburgh, where a test was created to detect the disease in the brain earlier.

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...